Abhijit Raval, MD
Pulmonary Disease · Anderson, SCNPI 1508052275
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,572,489 of the $1,977,603 with a category attached, or 79.5%. It is spread thinly across 51 manufacturers, the largest accounting for just 15.8%. Among pulmonary disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,999 payments — averaging $989.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$313K
- United Therapeutics Corporation$292K
- GSK$264K
- Sanofi$203K
- Intuitive Surgical$162K
- AstraZeneca$158K
- plus $585K from 45 others
Across 348 payments — averaging $3016.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$578K
- United Therapeutics Corporation$208K
- E.r. Squibb & Sons, L.L.C.$75K
- Janssen Research & Development, LLC$47K
- Merck$44K
- Gyrus ACMI, Inc.$25K
- plus $74K from 7 others
What the payments were for
- Consulting fees$120,8926%
- Speaking & faculty fees$1,572,48980%
- Travel & lodging$100,5715%
- Food & beverage$36,8052%
- Education$146,8077%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$301,723
- UPTRAVI$275,025
- OPSUMIT$246,247
- TRELEGY ELLIPTA$180,375
- Da Vinci Surgical System$158,786
- TYVASO$154,782
- Arikayce$89,599
- Yupelri$88,083
- ANDEXXA$77,990
- Adempas$77,542
- BREZTRI$68,293
- ACTHAR$57,107
- ORENITRAM$50,488
- REMODULIN$43,936
- OFEV$34,927
- WINREVAIR$33,003
- NONE$24,385
- VELETRI$13,572
- DALIRESP$4,939
- ANORO ELLIPTA$4,800
How this compares
$1,977,603 in reported general payments places this provider in the 95th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 264 | $3,275,424 |
| UptraviSelexipag | 95 | $2,667,536 |
| AdempasRiociguat | 141 | $2,054,149 |
| Tyvaso DpiTreprostinil | 79 | $1,834,667 |
| OfevNintedanib Esylate | 101 | $1,332,040 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 707 | $528,019 |
| Orenitram ErTreprostinil Diolamine | 71 | $458,884 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 36 | $397,848 |
| WinrevairSotatercept-Csrk | 17 | $241,384 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 288 | $225,142 |
| OpsynviMacitentan/Tadalafil | 16 | $192,971 |
| Dupixent PenDupilumab | 29 | $106,574 |
| Tadalafil | 174 | $93,033 |
| Bosentan | 12 | $92,815 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 133 | $82,281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi, Bosentan | $313,000 | $6,228,747387 claims |
| BayerAdempas | $78,418 | $2,054,149141 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $141,931 | $1,446,357290 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $264,336 | $604,187861 claims |
| Grifols USA, LLCProlastin C | $24 | $397,84836 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $158,474 | $257,812379 claims |
| MerckWinrevair | $40,853 | $241,38417 claims |
| Johnson & JohnsonXarelto | $21,842 | $13,51611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Anderson
- Kenneth WaltersAnderson$81K
- Charles ThompsonAnderson$24K
- Syed MalikAnderson$10K
- Emerald Rose BranchAnderson$8K
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.